Quest Diagnostics Inc (DGX) recently faced stock price oscillation, triggering investors to reassess its valuation. However, the strong long-term returns have kept the investment allure intact. Despite a price target reduction by Evercore ISI, the company introduced significant initiatives including an industry-first collaboration with Epic to enhance laboratory testing experiences. Furthermore, the introduction of AI companions to help patients comprehend lab test results is seen as an innovative stride in patient care. The company reported impressive Q3/Q4 2025 results and raised its guidance for 2025/2026, while also increasing its quarterly dividend by 7.5% to $0.86 per share. As part of its growth strategy, Quest Diagnostics launched a novel flow cytometry MRD Blood Test for Myeloma and partnered with Corewell Health for enhanced lab services in Michigan. Moreover, it achieved a coveted spot in Fortune's World's Most Admired Companies list for the 12th consecutive year.
Quest Diagnostics DGX News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 11 Apr 2026 15:26:04 GMT -
Rating 6
- Innovation 7
- Information 7
- Rumor 3
